Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris
- Disease/Condition
- Acne Vulgaris
- Drug/Device/Intervention
- topical minoxidil in Acne Vulgaris
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Chang Gung Memorial Hospital
- Location
- Taoyuan, Taiwan
- Phase
- Phase 1/2
- Start date
- Jul 11, 2023
- End date
- Dec 31, 2023
- Enrollment
- 26 participants
Change from baseline systolic blood pressure
Patients with acne vulgaris (AV) appeared to be a chronic inflammation with a wide range in
 teenagers and adult. The protocol design is as follows.
 
 The subjects enrolled through inclusion and exclusion criteria will undergo the blood and
 urine biochemical tests for baseline record. The photos from the subjects will be recorded
 per day, and the blood and urine biochemical tests will be recorded per week.
 
 Objectives: primary: to test the toxicity of topical minoxidil in treatment of acne vulgaris;
 second: to evaluate the response and disease control rate in this pilot study.
 
 Measurement: Time to resolution of individual acne lesions (14 days) Monitor of treatment
 efficacy: number of inflammatory acne lesions counting, time to resolution of individual acne
 lesion, and degree of acne severity measurement.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06108193
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06108193 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Chang Gung Memorial Hospital and is currently Recruiting. The study focuses on Acne Vulgaris. Target enrollment is 26 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.